CF
ATXS

Corebridge Financial’s Astria Therapeutics ATXS Stock Holding History

Corebridge Financial’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,672
Closed -$121K – 257
2025
Q1 		$121K Sell
22,672
-336
-1% -$2.35K ﹤0.01% 2344
2024
Q4 		$206K Sell
23,008
-1,073
-4% -$11.4K ﹤0.01% 2166
2024
Q3 		$265K Sell
24,081
-148
-0.6% -$1.65K ﹤0.01% 2059
2024
Q2 		$220K Buy
+24,229
New +$237K ﹤0.01% 2137

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Corebridge Financial's ATXS Position: Q2 2025 in Review

Corebridge Financial sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 22,672 shares — an estimated $121K sold.

Corebridge Financial first reported a position in ATXS in Q2 2024 and held it in 4 quarters. The position peaked at $265K in Q3 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Corebridge Financial reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 22,672 Astria Therapeutics shares in Q2 2025, an estimated $121K.
  • Corebridge Financial first reported a position in Astria Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Astria Therapeutics position peaked at $265K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.